The FDA was expected to issue EUA to Novavax COVID-19 vaccine
On Sunday, the Food and Drug Administration (FDA) said that it was expected to issue emergency use authorization (EUA) to Novavax COVID-19 vaccine, which was believed to be effective against COVID-19 variants — including the Delta COVID-19 variant.
In an interview on Dobol B TV, FDA Director-General Eric Domingo said that they’re possibly looking to issue EUA to Novavax COVID-19 vaccine, one of the COVID-19 vaccines developed in the United States and India.
Domingo also said that the said vaccine was very promising and seemed to be effective against the Delta COVID-19 variant.
“Ang possible so far ‘yung Novavax, isang bakuna na na-develop sa US and India na very promising din at mukhang maganda sa Delta variant. Nag-publish na sila ng result,” Domingo said.
READ ALSO: FDA, NBI To Look Into Alleged Selling Of COVID-19 Vaccines — Domingo
According to Domingo, the EUA approval of Novavax COVID-19 vaccine was still pending with India, UK, and America before they could complete their EUA application in the Philippines.
So far, the Philippine Food and Drug Administration granted EUA to vaccine manufacturers Pfizer and BioNTech (BNT162b2), AstraZeneca and Oxford University (AZD1222), Sinovac Biotech (CoronaVac), Gamaleya Institute (Sputnik V), Johnson & Johnson (Janssen), Bharat Biotech (Covaxin), and Moderna (mRNA-1273).
In a report on Reuters, Novavax said that its protein-based COVID-19 vaccine was more than 93% effective against the more contagious predominant COVID-19 variants.
What can you say about this? Let us know in the comments below.
For more news and updates, you may feel free to visit this site more often. You may also visit Newspapers.ph via our official Facebook page and YouTube channel.